Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

Autor: Frederik Barkhof, Chris H. Polman, Brian Hennessy, Giancarlo Comi, Nicola De Stefano, Bernard M. J. Uitdehaag, B Stubinski, Mark S. Freedman, Margaretha Stam Moraga, Florence Casset-Semanaz, Ludwig Kappos, Sanda Rocak

Publikováno v: Comi, G, De Stefano, N, Freedman, M S, Barkhof, F, Polman, C H, Uitdehaag, B M J, Casset-Semanaz, F, Hennessy, B, Moraga, M S, Rocak, S, Stubinski, B & Kappos, L 2012, ' Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial ', Lancet Neurology, vol. 11, no. 1, pp. 33-41 . https://doi.org/10.1016/S1474-4422(11)70262-9
Lancet Neurology, 11(1), 33-41. Lancet Publishing Group

In patients presenting with a first clinical demyelinating event that is suggestive of multiple sclerosis (MS), treatment with interferon beta can delay the occurrence of further attacks and the onset of MS. We investigated the effects of two dosing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b46e008a3b48bad23393b0c2d58a7095
https://doi.org/10.1016/s1474-4422(11)70262-9

The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings

Autor: Magnhild, Sandberg-Wollheim, Gabrielle, Kornmann, Dorina, Bischof, Margaretha Stam, Moraga, Brian, Hennessy, Enrica, Alteri

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England). 17(4)

Risks that are potentially associated with long-term therapies should be assessed.The present analyses were performed to determine the risk of malignancy in patients with multiple sclerosis (MS) receiving subcutaneous (sc) interferon (IFN) beta-1a, u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a97aef6247722de946bcf49533c90f00
https://pubmed.ncbi.nlm.nih.gov/21486902

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance

Autor: Jonathan Alsop, Alain Micaleff, Gordon S. Francis, Neil Kaplowitz, Yves Grumser, Fanny O’Brien, Enrica Alteri, Margaretha Stam Moraga

Publikováno v: Drug safety. 26(11)

Hepatic dysfunction, manifested as liver enzyme elevations, occurs frequently in patients who are treated with interferon, however, data for patients with multiple sclerosis are limited.To retrospectively assess the safety profile of interferon-beta-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::924f7edbbb1169c974b2ce49d4b5db0e
https://pubmed.ncbi.nlm.nih.gov/12908850

Abstracts of the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. October 19-22, 2011. Amsterdam, The Netherlands.

Publikováno v: Multiple Sclerosis Journal; Oct2011 Supplement, Vol. 17 Issue 10, pS9-S524, 516p

Subcutaneous Interferon -1a in Children and Adolescents with Multiple Sclerosis: An International Retrospective Study of 307 Patients (P04.119)

Autor: Brenda Banwell, Margot Stam Moraga, Silvia Tenembaum, Alexey Boyko, Lauren B. Krupp, Michel Meinel, Sanda Rocak, Angelo Ghezzi, Daniela Pohl

Publikováno v: Neurology. 78:P04.119-P04.119

Objective: To review the safety, tolerability, and efficacy of subcutaneous interferon β-1a (sc IFN β-1a) in children and adolescents with multiple sclerosis (MS). Background 3–10% of patients with MS present before 16 years; Design/Methods: A mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d44be56bdc0fea5c82a1a2027c32d999
https://doi.org/10.1212/wnl.78.1_meetingabstracts.p04.119